Woodley Farra Manion Portfolio Management Inc. Sells 570 Shares of Eli Lilly and Company $LLY

Woodley Farra Manion Portfolio Management Inc. cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,355 shares of the company’s stock after selling 570 shares during the quarter. Woodley Farra Manion Portfolio Management Inc.’s holdings in Eli Lilly and Company were worth $25,222,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Lazard Freres Gestion S.A.S. grew its stake in Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after acquiring an additional 39 shares during the period. Capital Advisors Inc. OK grew its position in shares of Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the last quarter. Family CFO Inc bought a new position in shares of Eli Lilly and Company during the second quarter worth approximately $54,000. Finally, Duquesne Family Office LLC lifted its holdings in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.2%

LLY opened at $1,024.67 on Friday. The stock has a market capitalization of $968.70 billion, a price-to-earnings ratio of 66.97, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,033.62. The company has a 50-day simple moving average of $826.89 and a 200 day simple moving average of $780.87.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period in the previous year, the company earned $1.18 EPS. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $886.00 to $1,104.00 in a report on Monday, November 10th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,015.11.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.